KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Research & Development (2016 - 2025)

AbbVie (ABBV) has disclosed Research & Development for 14 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • Quarterly Research & Development fell 61.93% to $2.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 billion through Dec 2025, down 28.89% year-over-year, with the annual reading at $9.1 billion for FY2025, 28.89% down from the prior year.
  • Research & Development for Q4 2025 was $2.6 billion at AbbVie, up from $2.3 billion in the prior quarter.
  • The five-year high for Research & Development was $6.8 billion in Q4 2024, with the low at $1.5 billion in Q1 2022.
  • Average Research & Development over 5 years is $2.1 billion, with a median of $1.9 billion recorded in 2021.
  • The sharpest move saw Research & Development skyrocketed 251.53% in 2024, then tumbled 61.93% in 2025.
  • Over 5 years, Research & Development stood at $1.8 billion in 2021, then decreased by 2.03% to $1.8 billion in 2022, then grew by 7.65% to $1.9 billion in 2023, then surged by 251.53% to $6.8 billion in 2024, then crashed by 61.93% to $2.6 billion in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $2.6 billion, $2.3 billion, and $2.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.